Stayble Therapeutics AB (OSTO:STABL) FCF Yield %: -44.79 (As of Jun. 29, 2026)


OSTO:STABL Stayble Therapeutics AB OSTO:STABL
28 GF Score
Price kr0.21
! 1 Warning Sign
View Full Analysis

What is Stayble Therapeutics AB FCF Yield %?

Stayble Therapeutics AB OSTO:STABL 28 FCF Yield % is -44.79 as of Jun. 29, 2026. GuruFocus rates OSTO:STABL with a GF Score™ of 28/100. The stock has 1 warning sign investors should review. Among 1,415 Biotechnology companies, Stayble Therapeutics AB ranks worse than 81.91% on this metric.

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Stayble Therapeutics AB's Trailing 12-Month Free Cash Flow is kr-5.91 Mil, and Market Cap is kr13.19 Mil. Therefore, Stayble Therapeutics AB's FCF Yield % for today is -44.79%.

The historical rank and industry rank for Stayble Therapeutics AB's FCF Yield % or its related term are showing as below:

OSTO:STABL' s FCF Yield % Range Over the Past 10 Years
Min: -44.79   Med: 0   Max: 0
Current: -44.79


OSTO:STABL's FCF Yield % is ranked worse than
81.91% of 1415 companies
in the Biotechnology industry
Industry Median: -9.62 vs OSTO:STABL: -44.79

Stayble Therapeutics AB's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.


Stayble Therapeutics AB FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Stayble Therapeutics AB FCF Yield % Related Terms


Stayble Therapeutics AB FCF Yield % Historical Data

* Premium members only.

The historical data trend for Stayble Therapeutics AB's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Stayble Therapeutics AB FCF Yield % Chart

Stayble Therapeutics AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -11.01 -44.93 -246.89 -65.77 -46.41

Stayble Therapeutics AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -28.08 -19.85 -42.54 -37.01 -38.31

OSTO:STABL vs VRTX, REGN, ALNY: FCF Yield % Comparison

For the Biotechnology subindustry, Stayble Therapeutics AB's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Stayble Therapeutics AB FCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Stayble Therapeutics AB's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Stayble Therapeutics AB's FCF Yield % falls into.


OSTO:STABL
28GF Score
Stayble Therapeutics AB OSTO:STABL
FCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Stayble Therapeutics AB FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Stayble Therapeutics AB's FCF Yield % for the fiscal year that ended in Dec. 2025 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-6.72 / 14.481
=-46.41%

Stayble Therapeutics AB's annualized FCF Yield % for the quarter that ended in Mar. 2026 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-1.35 * 4 / 14.09484
=-38.31%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Yield % →
What does a FCF Yield % of -44.79 mean?
Stayble Therapeutics AB (OSTO:STABL) has a FCF Yield % of -44.79 as of Jun. 29, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Stayble Therapeutics AB and its competitors. According to the industry distribution chart, Stayble Therapeutics AB ranks #1159 out of 1415 companies in the Biotechnology industry, placing it in the top 81.9%.
Is Stayble Therapeutics AB's FCF Yield % too high?
Stayble Therapeutics AB's current FCF Yield % is -44.79. Based on the distribution chart, Stayble Therapeutics AB ranks #1159 out of 1415 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Stayble Therapeutics AB has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Stayble Therapeutics AB's FCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Stayble Therapeutics AB ranks #1159 out of 1415 companies for FCF Yield %. This places Stayble Therapeutics AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Stayble Therapeutics AB and its competitors. Stayble Therapeutics AB's current FCF Yield % is -44.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stayble Therapeutics AB stock overvalued right now?
Stayble Therapeutics AB (OSTO:STABL) has a current FCF Yield % of -44.79. The current FCF Yield % is -44.79. Stayble Therapeutics AB's overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Stayble Therapeutics AB (OSTO:STABL), the current FCF Yield % is -44.79 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Stayble Therapeutics AB Business Description

Other Exchanges 4K4:Germany
Address Lennart Torstenssonsgatan 6, Gothenburg, SWE, 412 56
Stayble Therapeutics AB is a clinical-stage pharmaceutical company developing STA363, an intradiscally injected formulation against chronic discogenic low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and analgesics. The injection is given once and the effect is expected to remain throughout the patient's life and requires minimal rehabilitation. The company's injection treatment, STA363, is expected to correct the underlying cause of disc-related low back pain by affecting the two main causative factors namely instability of the disc and prevention of leakage of inflammatory mediators from the disc center.
28GF Score

Get the complete analysis for OSTO:STABL

FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.21
Price